PUFAs May Improve Outcome of Hypertriglyceridemia in HIV-treated Patients
In this double-blind, placebo-controlled, randomized, multicenter pilot study, researchers investigated the effects of the polyunsaturated fatty acids (PUFA), docosahexaenoic acid (DHA) 460 mg and eicosapentaenoic acid (EPA) 380 mg, on hypertriglyceridemia in HIV-treated patients. Subjects (n=48) were male HIV-infected patients undergoing highly active antiretroviral therapy (HAART), with fasting triglyceride levels of 3.39 to 11.3 mmol/L. Patients were allowed fibrate or niacin but not statins and were randomized to PUFAs, 4 g daily (n= 23, mean age=46.1 yrs) or placebo (n=25, mean age=43.6 yrs) for 12 weeks. The primary end point was mean fasting triglyceride levels. PUFA group had a mean body mass index of 24.7 kg/m(2); placebo group, 24.1 kg/m(2). All patients received concomitant fibrate therapy. Median baseline triglyceride levels were 5.58 (1.76-10.6) mmol/L for PUFA and 4.29 (1.81-6.14) mmol/L for placebo. PUFAs reduced triglycerides by a median of 1.75 mmol/L versus a 0.41 mmol/L increase for placebo. The authors conclude that PUFA therapy with DHA/EPA may reduce triglyceride levels in HIV-infected patients with HAART-associated hypertriglyceridemia.
Click Here to visit the journal website. Subscription required to view the full text of the article.